Search

everythinglearnresearchcommunity

for

Search:↓

Verteporfin might reverse severe hair loss but is still in early testing stages. It could be a future option for NW6-7, though expensive.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The user has been using a combination of treatments including Dutasteride, Minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy to address hair loss but continues to experience shedding and density loss. Despite high testosterone and iron levels, the user is frustrated with the lack of improvement and is considering adjusting treatment or exploring other options like a hair transplant.

A 24-year-old male reported a 7-month hairline recovery using 0.5mg of dutasteride daily with no side effects. Another user suggested adding minoxidil to the treatment.

The user has been using dutasteride for 8 months, oral minoxidil for 3 years, and topical minoxidil on temples, with recent microneedling. They experienced thinning after switching from finasteride to dutasteride and are hoping for improvement by the 12-month mark.

A 7-month progress report of using finasteride and minoxidil, as well as keto dieting and derma stamping; the discussion also touched on RU58841 and its potential side effects.

User has been using minoxidil for 5 years and recently started finasteride, 2% nizoral shampoo, low light level laser helmet, microneedling, and biotin supplement to prepare for a hair transplant. Another user suggests it's not too much and mentions additional treatments like dutasteride, oral min, RU, and pyrilutamide.

Hair loss progress and treatments, specifically oral dutasteride and oral minoxidil.

The user experienced initial success with topical finasteride 0.025% and melatonin but noticed rapid hair thinning after three months. They are considering switching to a higher dose of topical finasteride or oral finasteride, as advised by others, while being cautious about potential side effects.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

A user shared progress photos after 37 days of using 0.5mg dutasteride for hair loss at age 17. The discussion focuses on the effectiveness of this treatment.

A person had a successful hair transplant in Turkey with 3200 grafts using FUE and DHI techniques, and is satisfied with the results after 9 months. They have been using finasteride for 7 years to maintain hair health.

A 25-year-old man has been using topical minoxidil 5%, oral finasteride 1mg, and microneedling for hair loss treatment for 14, 9, and 8 weeks respectively. He experienced watery semen after starting finasteride, but it normalized after a few days with no other side effects.

A 27-year-old man is using a daily routine of 5% Minoxidil spray in the morning and a topical mix of 5% Minoxidil/0.1% Finasteride at night, along with microneedling. He reports significant hair improvement despite ongoing shedding.

A 21-year-old shares progress using oral dutasteride for 3 months and topical minoxidil 5% for 3 weeks, noting reduced hair shedding and new baby hairs. They seek feedback on when to expect noticeable thickening and hairline improvement.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

A 28-year-old has been using oral dutasteride 0.5 mg, topical minoxidil 5%, and Cafune shampoo for 104 days with positive results and is considering adding microneedling. No side effects from dutasteride have been reported.

A user shared progress pictures after 25 days of using Minoxidil, microneedling, and recently started topical finasteride for hair loss. Some commenters are skeptical about the results, while others notice new hair growth.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user shared progress pictures after 3 months of using topical finasteride, minoxidil, and microneedling for hair loss. They plan a hair transplant at 6 months, and others inquired about microneedling frequency and depth.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

The conversation discusses creating a foam version of RU58841 for easier application on thick hair, comparing it to minoxidil foam. The user currently uses dutasteride, minoxidil, and needling for hair loss treatment.

The user experienced hair loss due to androgenic alopecia and chose to use essential oils (rosemary and peppermint) and microneedling instead of minoxidil or finasteride. They reported positive results after 24 days and plan to continue with these treatments.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

The conversation discusses using tretinoin with topical minoxidil for hair regrowth, despite previous non-response to minoxidil and concerns about oral minoxidil's heart risks. The user is also on dutasteride and is considering a hair transplant if other options fail.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The user is using dutasteride, oral minoxidil, and topical minoxidil with tretinoin for hair loss. They are considering whether to continue this treatment or opt for a hair transplant for their temples.